Bacterial proteases in IBD and IBS

Proteases play a decisive role in health and disease. They fulfil diverse functions and have been associated with the pathology of gastrointestinal disorders such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The current knowledge focuses on host-derived proteases including matrix metalloproteinases, various serine proteases and cathepsins. The possible contribution of bacterial proteases has been largely ignored in the pathogenesis of IBD and IBS, although there is increasing evidence, especially demonstrated for proteases from pathogenic bacteria. The underlying mechanisms extend to proteases from commensal bacteria which may be relevant for disease susceptibility. The intestinal microbiota and its proteolytic capacity exhibit the potential to contribute to the pathogenesis of IBD and IBS. This review highlights the relevance of host- and bacteria-derived proteases and their signalling mechanisms.

[1]  M. Denis,et al.  TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. , 2009, International journal of molecular medicine.

[2]  J. Sallenave,et al.  Modifying the Protease , Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis JEAN – , 2011 .

[3]  M. Steinhoff,et al.  Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. , 2006, The American journal of pathology.

[4]  B. de Strooper,et al.  ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Michael A McGuckin,et al.  Intestinal barrier dysfunction in inflammatory bowel diseases. , 2009, Inflammatory bowel diseases.

[6]  M. Stacey,et al.  Interaction of Mite Allergens Der P3 and Der P9 with Protease-Activated Receptor-2 Expressed by Lung Epithelial Cells1 , 2001, The Journal of Immunology.

[7]  M. Steinhoff,et al.  Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.

[8]  A. Nusrat,et al.  Immunopathology and Infectious Diseases The Bacterial Virulence Factor Lymphostatin Compromises Intestinal Epithelial Barrier Function by Modulating Rho GTPases , 2010 .

[9]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[10]  A. Ford,et al.  IBS in 2010: Advances in pathophysiology, diagnosis and treatment , 2011, Nature Reviews Gastroenterology &Hepatology.

[11]  A. Franco,et al.  Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage , 2007, Journal of Cell Science.

[12]  Jung Ok Shim,et al.  Gut Microbiota in Inflammatory Bowel Disease , 2013, Pediatric gastroenterology, hepatology & nutrition.

[13]  P. Adamski,et al.  Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. , 2009, World journal of gastroenterology.

[14]  G. Macfarlane,et al.  Contribution of the microflora to proteolysis in the human large intestine. , 1988, The Journal of applied bacteriology.

[15]  W. W. Lathem,et al.  The StcE Protease Contributes to Intimate Adherence of Enterohemorrhagic Escherichia coli O157:H7 to Host Cells , 2005, Infection and Immunity.

[16]  Young‐Mi Lee,et al.  Expression of Protease-Activated Receptor 2 in Ulcerative Colitis , 2003, Inflammatory bowel diseases.

[17]  P. Brigidi,et al.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[18]  Takashi Shimizu,et al.  Serratia marcescens Serralysin Induces Inflammatory Responses through Protease-Activated Receptor 2 , 2006, Infection and Immunity.

[19]  J. Ballard,et al.  Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.

[20]  A. Azghani Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. , 1996, American journal of respiratory cell and molecular biology.

[21]  G. Rogler,et al.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo , 2006, Clinical and experimental immunology.

[22]  Anne Salonen,et al.  Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. , 2010, Microbiology.

[23]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Philip Sutton,et al.  Mucin dynamics and enteric pathogens , 2011, Nature Reviews Microbiology.

[25]  B. Kuster,et al.  Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. , 2011, Gastroenterology.

[26]  J. Potempa,et al.  Cleavage and activation of proteinase‐activated receptor‐2 on human neutrophils by gingipain‐R from Porphyromonas gingivalis , 1998, FEBS letters.

[27]  I. Autenrieth,et al.  Gene-environment interactions in chronic inflammatory disease , 2011, Nature Immunology.

[28]  A. Keshavarzian,et al.  Regulation of Oxidant-Induced Intestinal Permeability by Metalloprotease-Dependent Epidermal Growth Factor Receptor Signaling , 2007, Journal of Pharmacology and Experimental Therapeutics.

[29]  J. Platt,et al.  Conditional signaling by Toll‐like receptor 4 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  B. Oneda,et al.  The Metalloprotease Meprinβ Processes E-Cadherin and Weakens Intercellular Adhesion , 2008, PloS one.

[31]  T. Kirkegaard,et al.  Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium , 2009, Clinical and experimental immunology.

[32]  S. Bruno,et al.  Increased thrombin generation in inflammatory bowel diseases. , 2008, Thrombosis research.

[33]  P. Kenny Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer , 2007, Expert opinion on therapeutic targets.

[34]  R. Spiller Overlap between Irritable Bowel Syndrome and Inflammatory Bowel Disease , 2010, Digestive Diseases.

[35]  David F. Tunmore,et al.  The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. , 2000, The American journal of pathology.

[36]  E. Nemoto,et al.  Proteolysis of Human Monocyte CD14 by Cysteine Proteinases (Gingipains) from Porphyromonas gingivalis Leading to Lipopolysaccharide Hyporesponsiveness1 , 2000, The Journal of Immunology.

[37]  David C. Lee,et al.  An essential role for ectodomain shedding in mammalian development. , 1998, Science.

[38]  A. Steele,et al.  Anthrax lethal toxin induces endothelial barrier dysfunction. , 2005, The American journal of pathology.

[39]  S. Michalek,et al.  Characterization of Porphyromonas gingivalis-Induced Degradation of Epithelial Cell Junctional Complexes , 2000, Infection and Immunity.

[40]  J. Potempa,et al.  Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. , 2001, Blood.

[41]  G. Tannock The search for disease-associated compositional shifts in bowel bacterial communities of humans. , 2008, Trends in microbiology.

[42]  P. Cossart,et al.  Candida albicans internalization by host cells is mediated by a clathrin‐dependent mechanism , 2009, Cellular microbiology.

[43]  A. Tursi,et al.  Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[44]  S. Filler,et al.  Als3 Is a Candida albicans Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells , 2007, PLoS biology.

[45]  T. Kirkegaard,et al.  Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. , 2004, Clinical and experimental immunology.

[46]  G. Schneider,et al.  Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E‐cadherin to disrupt intercellular adhesion , 2010, EMBO reports.

[47]  F. F. di Mola,et al.  Beneficial Effects of Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in Rat Experimental Colitis , 2001, Digestion.

[48]  Y. Naito,et al.  Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis , 2006, Scandinavian journal of gastroenterology.

[49]  S. Rosewicz,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.

[50]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[51]  C. Rudack,et al.  Immunomodulation of Nasal Epithelial Cells by Staphylococcus aureus-Derived Serine Proteases1 , 2009, The Journal of Immunology.

[52]  F. Nagy,et al.  A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  M. Steinhoff,et al.  Protease‐activated receptor‐4 (PAR4): a role as inhibitor of visceral pain and hypersensitivity , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[54]  G. Gerken,et al.  Trypsin-Sensitive Modulation of Intestinal Epithelial MD-2 as Mechanism of Lipopolysaccharide Tolerance1 , 2006, The Journal of Immunology.

[55]  P. Cossart,et al.  E-Cadherin Is the Receptor for Internalin, a Surface Protein Required for Entry of L. monocytogenes into Epithelial Cells , 1996, Cell.

[56]  T. Wittmann,et al.  Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice , 2009, PAIN®.

[57]  N. Bunnett,et al.  Protease-activated receptors: protease signaling in the gastrointestinal tract. , 2004, Current opinion in pharmacology.

[58]  M. Kreis,et al.  Activity of protease-activated receptors in the human submucous plexus. , 2011, Gastroenterology.

[59]  M. Sinnamon,et al.  Essential role for mast cell tryptase in acute experimental colitis , 2010, Proceedings of the National Academy of Sciences.

[60]  M. D'Andrea,et al.  Arginine-Specific Protease fromPorphyromonas gingivalis Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion , 2001, Infection and Immunity.

[61]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[62]  T. Kirkegaard,et al.  Tumour necrosis factor‐α converting enzyme (TACE) activity in human colonic epithelial cells 1 , 2004 .

[63]  K. Magnusson,et al.  Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction‐associated proteins occludin and ZO‐1 , 2000, Cellular microbiology.

[64]  J. Kennedy,et al.  Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. , 1985, Gut.

[65]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[66]  Hannes Hahne,et al.  T2025 Probiotic-Derived Lactocepin Degrades the Pro-Inflammatory Chemokine IP-10: Impact on Chronic Intestinal Inflammation , 2010 .

[67]  M. Steinhoff,et al.  Protease‐activated receptor‐4: a novel mechanism of inflammatory pain modulation , 2007, British journal of pharmacology.

[68]  A. Azghani,et al.  A bacterial protease perturbs the paracellular barrier function of transporting epithelial monolayers in culture , 1993, Infection and immunity.

[69]  Liping Su,et al.  Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. , 2009, Gastroenterology.

[70]  G. Berx,et al.  The cell-cell adhesion molecule E-cadherin , 2008, Cellular and Molecular Life Sciences.

[71]  Michael A McGuckin,et al.  Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of Mucin by Other Bacteria , 2010, The American Journal of Gastroenterology.

[72]  J. D. de Paula,et al.  Colonic proteinases: increased activity in patients with ulcerative colitis. , 1998, Medicina.

[73]  C. Josenhans,et al.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models , 2010, Nature Reviews Microbiology.

[74]  M. Radomski,et al.  Matrix metalloproteinase‐9 modulates intestinal injury in rats with transmural colitis , 2006, Journal of leukocyte biology.

[75]  P. Garg,et al.  Matrix metalloproteinases in inflammatory bowel disease: Boon or a bane? , 2007, Inflammatory bowel diseases.

[76]  S. Vanner,et al.  Activation of protease‐activated receptor‐4 inhibits the intrinsic excitability of colonic dorsal root ganglia neurons , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[77]  C. Schultsz,et al.  The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. , 1999, Gastroenterology.

[78]  F. Bistoni,et al.  The contribution of PARs to inflammation and immunity to fungi , 2008, Mucosal Immunology.

[79]  P. Bercik,et al.  Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. , 2010, Infectious disease clinics of North America.

[80]  L. I. Bouwman,et al.  Cleavage and activation of a Toll-like receptor by microbial proteases , 2011, Proceedings of the National Academy of Sciences.

[81]  M. Chignard,et al.  Increased Proteolytic Activity at Mucosal Surfaces in IBD Patients: A Possible Role for Elafin , 2011 .

[82]  R. Langer,et al.  Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.

[83]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[84]  K. O'Byrne,et al.  Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  A. Nusrat,et al.  Role of the intestinal barrier in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[86]  M. Mareel,et al.  Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.

[87]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[88]  Parsons,et al.  The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease , 1999, Alimentary pharmacology & therapeutics.

[89]  Y. Higashimoto,et al.  A novel secreted protease from Pseudomonas aeruginosa activates NF‐κB through protease‐activated receptors , 2008, Cellular microbiology.

[90]  F. Shanahan,et al.  Degradation of the extracellular matrix components by bacterial‐derived metalloproteases: Implications for inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[91]  G. Barbara,et al.  Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.

[92]  J. d'Alayer,et al.  Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. , 2005, American journal of respiratory cell and molecular biology.

[93]  R Balfour Sartor,et al.  Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.

[94]  Y. Fujiyama,et al.  Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. , 1993, Internal medicine.

[95]  Paul Forsythe,et al.  Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium‐dependent potassium channel opening , 2009, Journal of cellular and molecular medicine.

[96]  Ruth Ley,et al.  Unravelling the effects of the environment and host genotype on the gut microbiome , 2011, Nature Reviews Microbiology.